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Summary In the present study, we determined the frequency and intensity of MRP protein expression by monoclonal antibody
immunohistochemistry in a series of 259 resected invasive primary breast carcinomas, and we evaluated MRP immunoreactivity in relation to
patient and tumour characteristics, relapse-free (RFS) and overall survival (OS). The immunostaining was graded on a semiquantitative scale
that ranged from (-) to (+++). Overall, 34% of the tumours were positive for anti-MRP antibody: 19% showed weak cytoplasmic staining (+),
14% had clear cytoplasmic staining (++) and only 1% of the tumours had a strong cytoplasmic as well as membranous staining (+++). MRP
expression was not related to patient's age, menopausal status, tumour size, differentiation grade, oestrogen and progesterone receptor level
or lymph node involvement. In an exploratory univariate analysis of all patients, only primary tumour size and number oflymph nodes involved
were significantly associated with shortened RFS (P < 0.001 and P < 0.001 respectively) and OS (P = 0.02 and P < 0.001 respectively). In
Cox univariate analysis for RFS in subgroups of patients stratified by menopausal status, tumour size, nodal status, adjuvant systemic
therapy and oestrogen and progesterone receptor status, MRP expression was associated with increased riskforfailure in patients with small
tumours (Ti), in node-negative patients and in node-positive patients who received adjuvant systemic chemotherapy with cyclophosphamide,
methotrexate and 5-fluorouracil (CMF); the relative hazard rate (RHR) for relapse was increased in the presence of MRP, with RHR values
with 95% confidence limits (CL) of 2.8 (1.2-6.9), 2.1 (1.0-4.2) and 2.8 (0.8-9.9) respectively. In analysis for OS, expression of MRP was also
associated with increased risk for failure in patients with small tumours (T1) [RHR (95% CL) 2.3 (0.9-6.0)] and in node-positive patients who
received adjuvant systemic chemotherapy with CMF [RHR (95% CL) 3.7 (0.8-17.1)] but not in node-negative patients [RHR (95% CL) 1.1
(0.4-2.6)]. In conclusion, our results show that MRP is frequently overexpressed in primary breast cancer and suggest that MRP expression
might be of prognostic significance in the subgroups of patients with the more favourable prognosis, i.e. patients with small tumours and node-
negative patients, as well as in the setting of adjuvant systemic chemotherapy. In primary breast cancer, MRP might be related to altered cell
biological behaviour, including a more aggressive phenotype, and resistance to adjuvant systemic chemotherapy.
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Breast canceris the most commonmalignancy among women inthe
Western world. Inpatients with operable disease, the axillary lymph
node status is one of the most important prognostic factors.
Approximately 40-50% ofpatients have tumourinvolvement ofthe
axillary nodes with a 10-year survival ofless than 50% (Henderson
et al, 1989). Of the node-negative patients, 70% can be cured by
surgery or breast-conserving treatment (McGuire and Clark, 1992).
The fact that even 30% of the node-negative patients relapse indi-
cates that in many instances breast cancer at diagnosis is a systemic
disease that consequently requires adjuvant systemic therapy with
hormones or cytotoxic drugs. The occurrence of drug resistance is
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one of the main obstacles for successful chemotherapy in breast
cancer. In vitro studies have revealed different mechanisms ofcyto-
toxic drug resistance in cancer cells, including energy-dependent
extrusion pumps (reviewed in Clynes, 1993; Goldstein and Ozols,
1994). Two members of the ATP-binding cassette superfamily of
transport proteins have been identified, the classical
170-kDa Pgp/MDRI and more recently the 190-kDa MRP, whose
overexpression makes cells multidrug resistant (MDR) in vitro
against natural product anti-cancer drugs. After the discovery of
PgplMDRI as a pump for anti-cancer drugs, it was initially thought
that the molecule would play a decisive role in tumour responsive-
ness to chemotherapy in the majority ofpatients. However, for the
frequently occurring human cancers, including cancers of the lung
and breast, a role for PgplMDRI in clinical drug resistance has still
not been established unequivocally (Lai et al, 1989; Merkel et al,
1989; Doyle, 1993; Nooter and Sonneveld, 1994; Linn et al, 1995).
Themultidrug resistance-associated protein (MRP) gene (Cole et al,
1992) encodes a 190-kDa membrane-bound glycoprotein of 1531
amino acids (Cole et al, 1992; Krishnamachary and Center, 1993;
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Childs and Ling, 1994; Hipfner et al, 1994). Transfection experi-
ments with different eukaryotic expression vectors containing full-
length complementary DNAs of the MRP gene have shown that
MRP confers resistance to a broad range of natural product drugs,
among which are anthracyclines, vinca alkaloids and epipodophyl-
lotoxins (Grant et al, 1994; Kruh et al, 1994; Zaman et al, 1994). As
yet, the mode of action by which MRP makes cells MDR is not
known. However, the available data suggestthat MRP acts both as a
plasmamembraneoutward drug pump andas apumpfordrug accu-
mulation in intracytoplasmic vesicles (Cole etal, 1994; Zaman et al,
1994; Breuninger et al, 1995; Paul et al, 1996). By both mecha-
nisms, cytoplasmic concentrations of free drug may be reduced to
sublethal levels, and in that way MRP would promote cell survival.
The association of MRP with clinical drug resistance has not
been elaborated yet, and studies on MRP expression in human
cancers have just begun. Expression of MRP has been demon-
strated in avariety ofsolid tumours (Bordow etal, 1994; Thomas et
al, 1994; Nooter et al, 1995, 1996a and b; Ota et al, 1995; Endo et
al, 1996; Filipits et al, 1996; Kavallaris et al, 1996) and leukaemias
(Burger et al, 1994a and b; Schneider et al, 1995). In a previous
study (Nooter etal, 1995), we determined the expression ofMRPin
Table 1 MRP expression in relation to patient, tumour and treatment
characteristics
MRP staining
Variable rr Positiveb (%) Pvalue
All patients 259 34
Age (years)
< 40 26 42
> 40-55 81 31
>55-70 97 29
> 70 55 42 0.39d
Menopausal status
Premenopausal 90 31
Post-menopausal 169 35 0.54e
Tumour size
Ti (<2cm) 76 30
T2 (> 2-5 cm) 148 34
T3-4 (> 5 cm) 33 36 0.76e
Nodal status
NO 101 34
N 1-3 61 30
N> 3 97 36 0.70e
Differentiation grade
l+11 33 24
III 170 36 0.18e
ERc
Negative 62 44
Positive 194 31 0.38d
PgRc
Negative 87 40
Positive 168 31 0.13d
Adjuvant treatment
No 198 34
Yes 61 31 0.64e
aNote that information on all variables was not always available. bPercentage
of tumours showing MRP staining (IHC score: +, ++ and +++). cCytosolic
values were used, with cut-off points set at 10 fmol mg-" protein. dTwo-
sample Wilcoxon rank-sum test. ePearson's X2 test.
normal tissues and in about 370 human tumour biopsies using a
quantitative RNAase protection assay and immunohistochemistry
(IHC). MRP appeared to be ubiquitously expressed at low levels in
all normal tissues, including peripheral blood cells, endocrine
glands, the lymphoreticular system and the digestive, respiratory
and urogenital tract. The human cancers analysedcould be divided,
based on intensity and frequency of expression, into several MRP
expression groups. In that particular study, and in a subsequent
study in non-small-cell lung cancer (Nooter et al, 1996a), RNAase
protection assay was compared with IHC for the detection ofMRP
expression, and we showed that, primarily because of the avail-
ability of high-affinity MRP-specific monoclonal antibodies
(MAbs) (Flens et al, 1994; MRPm6 and MRPrl), IHC is the tech-
nique ofchoice forthe detection ofMRP in clinical samples. In the
present study we determined the expression of MRP in resected
breast tumour samples using the MRP-specific MAb MRPrl, and
related MRP immunoreactivity to patient and tumour characteris-
tics, relapse-free (RFS) and overall survival (OS).
MATERIALS AND METHODS
Patients and tumour samples
Primary breast tumour specimens from a total of300 patients were
analysed for expression of MRP. In principle, only patients with
primary diagnosis of invasive breast cancer without metastatic
disease at or within 1 month of primary surgery were included in
the study. All patients underwent primary surgery in our center
(Daniel den Hoed Kliniek) or were referred for radiotherapy after
surgery between 1982 and 1990. Tumour samples were obtained
byresection, immediately frozen and stored in liquidnitrogen until
use. Of the 300 patients analysed for MRP expression, 259 could
be included in an analysis ofRFS and OS. Forty-one patients were
excluded from further evaluation for the following reasons: for 10
patients, the tumour could not be analysed because of freezing
artefacts; for 18 patients, the resected tumour appeared to have an
additional carcinoma in situ component; for three patients, the
tumour showed abundant lymphocytic infiltration; and finally for
10 patients, the tumour showed an aberrant MRP staining pattern.
This aberrant MRP staining consisted of strong myoepithelial
staining in one case, and in nine cases MRP staining was only
focally present in the tumour, i.e. the staining was restricted to an
area ofa few, weakly stained cells. The median age ofthe patients
(n = 259) at the time ofsurgery was 59 years (range 25-89 years).
All patients were routinely examined every 3-6 months during the
first 5 years of follow-up and once a year thereafter. The median
follow-up time ofpatients still alive was 64 months (range 8-127
months). Of the 259 patients, 119 experienced a relapse during
follow-up and 93 patients died. These patients counted as failures
in the analysis for RFS and OS. None of the 101 node-negative
patients had received adjuvant systemic treatment. Of the 158
node-positive patients, 37 had received adjuvant systemic
chemotherapy. In 32 of these patients, chemotherapy consisted of
cyclophosphamide, methotrexate and 5-fluorouracil (CMF).
Twenty-four patients received adjuvant hormonal therapy (mainly
tamoxifen), and three patients had combined hormono-
chemotherapy. The characteristics of the patients with respect to
age and menopausal status at the time of surgery, tumour size,
nodal status, differentiation grade of the tumour and oestrogen
(ER) and progesterone receptor (PgR) status are listed in Table 1.
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Table 2 Univariate Cox regression analysis of relapse-free and overall survival as a function of patient and tumour characteristics in all patients
Relapse-free survival Overall survival
Variable RHRa 95% CLb P-value RHRa 95% CLb P-value
Age and menopausal status 0.81 0.30
Age premenopausal 0.81 0.50-1.30 0.84 0.47-1.52
Age post-menopausal 1.03 0.80-1.33 1.24 0.93-1.64
Post- vs premenopausal 1.16 0.56-2.38 1.20 0.50-2.88
Tumour size < 0.001 0.02
T2 vs Ti 2.40 1.46-3.92 1.96 1.14-3.35
T3-4 vs Ti 3.95 2.14-7.31 2.45 1.21-4.99
Nodal status < 0.001 < 0.001
N1-3 vs NO 1.16 0.66-2.03 1.31 0.67-2.54
N> 3 vs NO 3.89 2.54-5.97 4.67 2.81-7.75
ERc
Positive vs negative 0.81 0.54-1.23 0.33 0.67 0.43-1.06 0.09
PgRc
Positive vs negative 1.00 0.68-1.47 0.99 0.69 0.45-1.05 0.09
MRPc
Positive vs negative 1.26 0.87-1.82 0.23 1.16 0.76-1.78 0.49
aRHR, relative hazard rate. b95% CL, 95% confidence limits. cPositive vs negative: 2 10 vs < 10 fmol mg-1 protein for ER and PgR, and any MRP staining
(IHC score: +, ++ and +++) vs no staining (IHC score: -).
Table 3 Univariate Cox regression analysis of relapse-free survival as a function of MRP expression in subgroups of patients
Relapse-free survival
Variable fr RHRb 95% CLc Failuresd
MRP positive MRP negative MRP positive MRP negative
All patients 87 172 1.3 0.9-1.8 44 75
Menopausal status
Premenopausal 28 62 1.3 0.7-2.4 16 28
Post-menopausal 59 110 1.2 0.8-2.0 28 47
Tumour size
pTl 23 53 2.8 1.2-6.9 10 10
pT2 51 97 1.2 0.7-1.8 28 49
pT3+4 12 21 0.7 0.3-1.8 6 15
Nodal statuse
NO 34 67 2.1 1.0-4.2 15 17
N+ 53 105 1.0 0.7-1.6 29 58
Adjuvant treatment
n+: None 34 63 0.8 0.5-1.4 19 44
n+: CMFf 7 25 2.8 0.8-9.9 4 6
n+: Tamoxifen 11 13 1.3 0.4-4.4 6 5
ER
Negative 27 35 0.8 0.4-1.7 12 18
Positive 60 134 1.4 0.9-2.2 32 57
PgR
Negative 35 52 1.0 0.5-2.0 15 23
Positive 52 116 1.4 0.9-2.2 29 52
an, Number of patients. Note that information on all variables was not always available. bRHR, relative hazard rate, c95% CL, 95% confidence limits. dFailures,
the number of relapses. en+, n > 0. 'CMF: cyclophosphamide, methotrexate and 5-fluorouracil.
Immunohistochemical detection and quantification
of MRP
Cryostat sections (5 gm) of tumour biopsies were fixed in cold
acetone (10 min, 0WC), air-dried and incubated for 60 min at 40C
with the MRP-specific monoclonal antibody (MAb) MRPrl as
described previously (Nooter et al, 1995; 1996a). Antibody
binding was detected using alkaline phosphatase-conjugated
immunoglobulin (Dako, Copenhagen, Denmark) and alkaline
phosphatase substrate using new fuchsin (Dako). The slides were
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counterstained with haematoxylin and mounted. The specificity of
MRPrl has been documented in detail elsewhere (Burger et al,
1994a; Flens et al, 1994). The MAb is suitable for protein blot
analysis, flow cytometry and immunohistochemistry (IHC) and
does not cross-react with the human MDR1 and MDR3 Pgps.
Before use, MRPrl was diluted (1:1500) in Tris-buffered saline
(50 mm Tris pH 7.4) containing normal rabbit serum (10%, w/v),
normal goat serum (1%, w/v) and normal human AB serum (1%,
w/v). Each assay included the use ofan isotype-matched irrelevant
MAb (rat IgG2a). Cytospin preparations of the MRP-over-
expressing doxorubicin-resistant human lung cancer cell line
GLC4/ADR and its drug-sensitive parental line GLC4 were used as
positive and negative controls respectively (Zaman et al, 1993).
Staining of the tumour cells was scored on the following semi-
quantitative scale: negative with only weak staining ofthe stromal
tissues (-); weak cytoplasmic staining of the tumour cells (+);
clear cytoplasmic staining of the tumour cells (++); and strong
cytoplasmic and membraneous staining ofthe tumour cells (+++).
The MRP staining was scored by two independent observers
(GBdlR and KvW), one of whom is a board-certified pathologist
(GBdlR) and who had no further clinical information of those
patients whose tumours were analysed.
Steroid receptor assays
ER and PgR levels were determined within 1 month after surgery
with radioligand binding assays, as recommended by the EORTC
(EORTC Breast Cancer Cooperative Group, 1980), or with
enzyme immunoassays (Abbott Laboratories, IL, USA), as
described previously (Foekens et al, 1989).
Statistical analysis
The association ofMRP expression with patient and tumour char-
acteristics was tested non-parametrically with the two-sample
Wilcoxon rank-sum test for continuous variables (age, ER, PgR)
or with the Pearson's X2 test for categorical variables (menopausal
status, tumour size, nodal status, differentiation grade, adjuvant
treatment). The Cox proportional hazards model was applied for
both univariate and multivariate analyses using the associated like-
lihood ratio test to test for differences. RFS and OS probabilities
were calculated by the actuarial method of Kaplan and Meier
(1958). For all tests, a two-sided P-value below 0.05 was consid-
ered to be statistically significant.
RESULTS
MRP expression in primary breast cancer
Expression ofMRP was determined by IHC with MRPrl on cryo-
stat sections of primary breast cancer specimens, and the expres-
sion was correlated with specific patient and tumourcharacteristics,
and RFS and OS. The MRPrl antibody reacted abundantly with the
MRP-positive control cell lineGLC4/ADR, whereas in the parental
cell line GLC4, no staining was observed. The GLC4/ADR cells
showed membrane staining as well as cytoplasmic staining, as
Table 4 Univariate Cox regression analysis of overall survival as a function of MRP expression in subgroups of patients
Overall survival
Variable rr RHRb 95% CLc Failuresd
MRP positive MRP negative MRP positive MRP negative
All patients 87 172 1.2 0.8-1.8 33 60
Menopausal status
Premenopausal 28 62 1.2 0.5-2.7 9 19
Post-menopausal 59 110 1.1 0.7-1.9 24 41
Tumour size
pTl 23 53 2.3 0.9-6.0 8 9
pT2 51 97 1.1 0.7-1.9 21 40
pT3+4 12 21 0.7 0.2-2.1 4 10
Nodal statuse
NO 34 67 1.1 0.4-2.6 7 14
N+ 53 105 1.2 0.8-2.0 26 46
Adjuvant treatment
n+: None 34 63 1.0 0.5-1.7 18 36
n+: CMF' 7 25 3.7 0.8-17.1 3 4
n+: Hormonal 11 13 1.1 0.3-4.2 5 4
ER
Negative 27 35 1.0 0.5-2.2 11 15
Positive 60 134 1.2 0.7-1.9 22 45
PgR
Negative 35 52 1.2 0.6-2.3 15 20
Positive 52 116 1.1 0.6-1.9 18 39
an, Number of patients. Note that information on all variables was not always available. bRHR,
the number of deaths. en+, n > 0. 'CMF: cyclophosphamide, methotrexate and 5-fluorouracil.
relative hazard rate. c95% CL, 95% confidence limits. dFailures,














































cells stained, whileforthe strongerstained tumours (IHC score: ++,
MRP negative +++) this figure was, in general, more than 50%.
MRP expression in relation to patient and tumour
characteristics
MRP positive In order to assess whether MRP expression at diagnosis was
related to patient and tumour characteristics, the patients were
stratified into two groups, MRP positive and MRP negative. The
MRP-negative group completely lacked MRP expression (IHC
score: -), whereas the MRP-positive group comprised all patients
60 with MRP staining (IHC score: + to +++). In Table 1 the
40 percentage ofMRP-positive tumours is listed in relation to patient
13 (age and menopausal status), tumour (size and grade ofdifferenti-
ation of the tumour, ER and PgR status and lymph node involve-
ment) and treatment characteristics (adjuyant treatment). No
MRP negative significant differences in MRP staining were detected according to
patient's age, menopausal status, tumour size, nodal status, differ-
entiation grade, ER and PgR. In addition, the distribution of
MRP expression in tumours ofpatients who did or did not receive






Figure 1 Actuarial relapse-free survival as a function of MRP status in node-
negative patients (A) and in patients with tumours < 2 cm (B). -, MRP-
positive patients; -, MRP-negative patients. The number of patients at risk
is indicated
documented previously (Nooter et al, 1995; 1996a). The MRP
staining among the primary breast carcinomas varied between
negative (-) and strong cytoplasmic and membraneous staining of
the tumour cells (+++). The specificity of the staining was shown
by using an isotype-matched, irrelevant rat MAb (IgG2a subclass)
that was always negative. The cytoplasmic and membrane staining
of MRP in the tumour cells is consistent with the idea that MRP
functions as a membrane-bound drug extrusion pump and is
involved in cytoplasmic drug sequestration. Based on staining
intensity and cellular localization of the staining, the breast cancer
specimens were qualitatively divided into four groups (IHC score:
-, +, ++, +++). Expression ofMRP (IHC score: +, ++ and +++) was
observed in 87 (34%) ofthe 259 tumour samples studied, while 172
(66%) of the samples had no detectable MRP staining and were
scored as negative (-). Forty-nine (19%) of the 259 samples
showed weak cytoplasmic staining (+), 35 (14%) had a clear cyto-
plasmic staining (++), and in only three (1%) a strong cytoplasmic
as well as membraneous staining (+++) of tumour cells was
observed. The intensity ofthe staining in the highest MRP staining
group (IHC score: +++) equals more or less the intensity observed
in the MRP-positive, drug-resistant GLC4/ADR cells. As the
intensity of the MRP staining increased, the percentage of stained
tumour cells increased also. Tumours with weak cytoplasmic
staining (IHC score: +) had mostly between 30-50% ofthe tumour
MRP expression in relation to relapse-free and overall
survival
To evaluate the prognostic significance of MRP expression at
diagnosis, MRP expression was analysed in relation to RFS and
OS. In a Cox univariate analysis for RFS and OS in all patients, no
significant relationship between MRP and RFS and OS was
observed (Table 2). Similarly, age, menopausal status, ER and PgR
were not significantly related to RFS and OS in univariate
analysis. On the otherhand, the size ofthe primary tumour and the
number of lymph nodes involved were significantly associated
with a shortened RFS and OS (Table 2). In accordance with Cox
univariate analysis, multivariate analysis showed that MRP
expression was not significantly associated with prognosis.
Subsequently, we performed an exploratory Cox regression
analysis for RFS and OS in subgroups of patients stratified by
menopausal status, tumour size, nodal status, adjuvant systemic
therapy, and ER and PgR status (Tables 3 and 4). For each
subgroup, the number of patients positive and negative for MRP
are shown. In Tables 3 and 4, the relative risk for failure expressed
as RHR with its 95% CL is given in relation to expression ofMRP
in the primary tumour (MRPpositive vs MRP negative). ForMRP-
negative tumours, the RHR = 1 by definition. We have not given
the P-values as the power of the Cox regression analysis is low
when only a limitednumberoffailures and small groups ofpatients
are available. In three subgroups, MRP expression was associated
with increased risk for failure. In patients with small tumours (TI),
in node-negative patients and in node-positive patients who
received adjuvant systemic chemotherapy with CMF, the RHR for
relapse was increased in the presence of MRP (Table 3: RHR 2.8,
2.1 and 2.8 respectively). The relationship of MRP to RFS in the
subgroup ofpatients with small tumours (TI) and in node-negative
patients is shown in Figure 1. The numbers of patients at risk are
indicated in the figures. In analysis forOS, expression ofMRP was
also associated with increased risk for failure inpatients with small
tumours (Ti) and in node-positive patients who received adjuvant
systemic chemotherapy with CMF but not in node-negative
patients (Table 4: RHR 2.3, 3.7 and 1.1 respectively).
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DISCUSSION
A large number ofcell biological parameters (reviewed in Klijn et
al, 1993), including oncogenes, tumour-suppressor genes, growth
factor and hormone receptors, and secretory proteins, have been
found to influence tumour behaviour with respect to metastatic
pattem, cellular differentiation, growth rate and the development
of therapy resistance. In the present study, we determined the
expression of the drug-resistance MRP gene in a series of more
than 250 primary breast cancer specimens, and we evaluated its
expression in relation to patient and tumour characteristics, and
RFS and OS. By IHC using the high-affinity MAb MRPrl (Flens
et al, 1994), expression ofMRP protein was found in about 30% of
primary breast carcinomas. The majority of these samples had
weak to moderate MRP expression levels, and only 1% of the
primary breast cancer specimens had strong MRP staining in the
cytoplasm and on the cell membrane. These results are in agree-
ment with preliminary data from our own group (Nooter et al,
1995) and those of others (Filipits et al, 1996). In a previous study
(Nooter et al, 1995), we found expression of MRP mRNA, as
determined by RNAase protection assay, in approximately 80% of
breast cancer specimens. In the same study, MRP protein was
found to be expressed in 2 of 11 breast cancer specimens only. In a
recent paper by the group of Pirker (Filipits et al, 1996), all
primary breast cancer specimens expressed MRP mRNA as deter-
mined by reverse transcriptase-polymerase chain reaction. By
IHC with two MRP-specific MAbs (QCRL-1 and QCRL-3) devel-
oped by the group of Cole and Deeley (Hipfner et al, 1994), strong
staining was observed in 24% and weak staining in the remaining
76% of the breast cancer specimens (Filipits et al, 1996). From
these studies it might be concluded that MRP mRNA is expressed
at a very low level in most breast cancer specimens and that a
smaller part (20-40%) of the specimens have elevated levels of
MRP. The ubiquitous, low-level expression of MRP mRNA in
breast cancer is in concordance with the MRP expression in the
normal, unaffected mammary gland (Flens et al, 1996). MRP was
detected at the protein level in different types of normal epithelial
cells from the bronchus, digestive tract and adrenal cortex (Flens
et al, 1996), suggesting that MRP may have an excretory function
in protecting the organism against xenobiotics. In the mammary
gland, the lobules were negative for MRP, while in the lactiferous
ducts some weak, focal expression could be detected.
In the current study, MRP expression at diagnosis was not
related to patient's age and menopausal status, tumour size and
differentiation grade, ER and PgR level or lymph node involve-
ment. However, in the study by Filipits et al (1996), strong MRP
staining was more frequent in T3 and T4 tumours than in TI and
T2 tumours but was also independent of age, menopausal status,
histology, histological grade, ER and PgR, and lymph node
involvement. We have shown here that, in Cox univariate analysis
of all patients, only primary tumour size and the number of lymph
nodes involved were significantly associated with a rapid rate of
relapse and shorter OS, which is a general finding that has been
reported previously by others (reviewed in Harris et al, 1992).
Age, menopausal status, ER and PgR status, and MRP expression
were not significantly related with the length of RFS and OS. In
Cox univariate analysis for RFS in subgroups ofpatients stratified
by menopausal status, tumour size, nodal status, adjuvant systemic
therapy, and ER and PgR status, MRP expression was associated
with increased risk for failure in patients with small tumours (TI),
in node-negative patients and in node-positive patients who
received adjuvant systemic chemotherapy with cyclophos-
phamide, methotrexate and 5-fluorouracil. The rate ofrelapse was
dramatically increased (2.1- to 2.8-fold) in the presence of MRP.
In analysis for OS, expression of MRP was also associated with a
2.3-fold increased death rate in patients with small tumours (TI)
and a 3.7-fold increased death rate in node-positive patients who
received adjuvant systemic chemotherapy with CMF but not in
node-negative patients. Apparently, inpatients with small tumours
and in node-negative patients, MRP expression might be associ-
ated with shorter RFS and OS. As these patients had not received
any systemic therapy, our data suggest that MRP expression in
primary breast cancer might be related to a more aggressive
tumour cell behaviour. For the classical 170-kDa Pgp/MDRI gene
product, such a correlation has also been documented in a variety
of different cancers, among which are colon (Weinstein et al,
1991), breast (Linn et al, 1995) and renal cell carcinomas (Tobe et
al, 1995). For these cancers, evidence was provided that Pgp
expression and tumour invasiveness may be linked. However, the
apparent association between Pgp expression and a more malig-
nant phenotype is not a universal phenomenon. In childhood rhab-
domyosarcoma, Pgp expression at diagnosis, in fact, appeared to
be associated with better RFS and OS (Kuttesch et al, 1996).
Nevertheless, together these studies suggest that Pgp might indeed
influence tumour cell behaviour.
Although normal tissue distribution and expression of MRP in
solid tumours and leukaemias has been documented, so far only
limited data are available on the clinical relevance of MRP in
human malignancies. Some recent studies (Bordow et al, 1994;
Kuss et al, 1994; Ota et al, 1995) suggest, based on historical data,
a correlation between clinical response to chemotherapy and level
of MRP expression. One study (Kuss et al, 1994) reported the
absence of MRP expression as a result of chromosomal aberra-
tions in a subgroup of drug-sensitive (daunorubicin and ara-C)
AML (M4), with inversion of chromosome 16. Another study
(Bordow et al, 1994) suggested the complementary correlation of
increased MRP expression in aggressive, notorious drug-resistant
neuroblastomas with N-myc oncogene amplification. Expression
of the MRP gene was correlated with amplification and over-
expression of the N-myc oncogene, especially in advanced-stage
tumours that tend to be particularly aggressive and unresponsive to
chemotherapy. In squamous cell carcinoma of the lung, the prog-
noses of patients with MRP expression were significantly worse
than those ofpatients without MRP expression (Ota etal, 1995). In
the present study, MRP expression in adjuvant CMF-treated, node-
positive patients was associated with duration of RFS and OS,
suggesting that MRP expression might encode drug resistance in
vivo against adjuvant systemic chemotherapy. In this respect, it is
of note that as yet none ofthe drugs in the CMFregimen has been
shown to be a substrate for MRP. In particular, in analysis for OS,
the absence of MRP expression was associated with a prolonged
survival. Of these node-positive CMF-treated patients, 92% were
still alive after 5 years compared with 57% for the patients with a
positive MRP score. Although very suggestive, these data are
based on small patient numbers and should therefore be consid-
ered carefully; they should rather be used as indication for future
studies. In conclusion, our results show that MRP is frequently
overexpressed in primary breast cancer and suggest that MRP
expression might be ofprognostic significance in the subgroups of
patients with a more favourable prognosis, i.e. patients with small
tumours and node-negative patients, as well as in the setting of
adjuvant systemic chemotherapy. Further studies with larger
British Journal ofCancer (1997) 76(4), 486-493 0 CancerResearch Campaign 1997492 KNooter etal
patient populations should confirm whether in primary breast
cancer MRP is related to altered cell biological behaviour,
including a more aggressive phenotype, and resistance to adjuvant
systemic chemotherapy.
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